Tom Dorsett has 27 years of experience as a healthcare entrepreneur and business development executive. He founded and exited two successful companies, NuScribe and ePatientFinder, and co-founded RazorMetrics in 2018 to lower drug spend for self-funded employers and health plans.
Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns.
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Every health plan is required to use real-time benefit tools, which allow physicians to access drug pricing and a patient’s benefit information at the point of care. But, to date, RTBTs haven’t delivered on the promised savings.
Minorities—along with the elderly and women—have historically been underrepresented in clinical trials.